Table of Contents
Editorial
COVID-19 vaccines: Equitable access, vaccine hesitancy and the dilemma of emergency use approvals | |
Ames Dhai | 77 |
Funding considerations for the use of experimental therapies for COVID-19 in the South African private sector | |
Z Adam, R J Wiseman | 79 |
COVID-19 millionaires must be held criminally accountable | |
S Mahomed, G Loots, G Andrews | 81 |
Contents
Contents | |
Articles
Resource allocation during COVID-19: A focus on vulnerable populations | |
C de V Castelyn, I M Viljoen, A Dhai, M S Pepper | 83 |
‘Please confirm your HIV-positive status by email to the following government address’: Protection of ‘vulnerable employees’ under COVID-19 | |
D T Hagemeister, M R Mpeli, B E Shabangu | 91 |
The HPCSA’s telemedicine guidance during COVID-19: A review | |
B A Townsend, M Mars, R E Scott | 97 |
Sharing human biobank samples and data in exchange for funding in South Africa in international collaborative health research – an ethicolegal analysis | |
M Maseme, S Mahomed | 103 |
Factors influencing truth-telling by healthcare providers to terminally ill cancer patients at Ocean Road Cancer Institute in Dar-es-Salaam, Tanzania | |
R Athanas, F Gasto, S J Renatha | 108 |
Prohibited substance regulation and compliance testing: A principalism approach | |
J B Laurens, P A Carstens | 114 |
Factors associated with refusal of hospital treatment at Odi District Hospital, Gauteng Province, South Africa | |
D K Nzaumvila, L H Mabuza, M Mogotsi, T Bongongo, C N Saidiya | 119 |
Multidisciplinary specialist treatment teams and abandonment of patients – who is responsible for what? | |
D J McQuoid-Mason | 125 |
Managed healthcare: Treatment protocols and fiduciary duties of funders | |
D Masege, A Dhai | 129 |
CPD questions
CPD questionnaire | |